These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 14707786)

  • 41. Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1.
    Liu H; Hwangbo Y; Holte S; Lee J; Wang C; Kaupp N; Zhu H; Celum C; Corey L; McElrath MJ; Zhu T
    J Infect Dis; 2004 Sep; 190(6):1055-8. PubMed ID: 15319853
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunologic profile of highly exposed yet HIV type 1-seronegative men.
    Yang OO; Boscardin WJ; Matud J; Hausner MA; Hultin LE; Hultin PM; Shih R; Ferbas J; Siegal FP; Shodell M; Shearer GM; Grene E; Carrington M; O'Brien S; Price CB; Detels R; Jamieson BD; Giorgi JV
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1051-65. PubMed ID: 12396457
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Haplotypes in CCR5-CCR2, CCL3 and CCL5 are associated with natural resistance to HIV-1 infection in a Colombian cohort.
    Vega JA; Villegas-Ospina S; Aguilar-Jiménez W; Rugeles MT; Bedoya G; Zapata W
    Biomedica; 2017 Jun; 37(2):267-273. PubMed ID: 28527291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CCR5 expression, haplotype and immune activation in protection from infection in HIV-exposed uninfected individuals in HIV-serodiscordant relationships.
    Jaumdally SZ; Picton A; Tiemessen CT; Paximadis M; Jaspan HB; Gamieldien H; Masson L; Coetzee D; Williamson AL; Little F; Gumbi PP; Passmore JS
    Immunology; 2017 Aug; 151(4):464-473. PubMed ID: 28398593
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of the CCR5Delta32 mutation in Brazilian populations and cell susceptibility to HIV-1 infection.
    Grimaldi R; Shindo N; Acosta AX; Dourado I; Brites C; de Melo Carvalho O; Brito I; Bou-Habib DC; Galvão-Castro B
    Hum Genet; 2002 Jul; 111(1):102-4. PubMed ID: 12136242
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure.
    Paxton WA; Martin SR; Tse D; O'Brien TR; Skurnick J; VanDevanter NL; Padian N; Braun JF; Kotler DP; Wolinsky SM; Koup RA
    Nat Med; 1996 Apr; 2(4):412-7. PubMed ID: 8597950
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The high frequency of HIV type 1-specific cellular immune responses in seronegative individuals with parenteral and/or heterosexual HIV type 1 exposure.
    Murashev BV; Nazarenko OV; Akulova EB; Artemyeva AK; Verevochkin SV; Shaboltas AV; Skochilov RV; Toussova OV; Kozlov AP
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1598-605. PubMed ID: 22475222
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Most highly exposed seronegative men lack HIV-1-specific, IFN-gamma-secreting T cells.
    Hladik F; Desbien A; Lang J; Wang L; Ding Y; Holte S; Wilson A; Xu Y; Moerbe M; Schmechel S; McElrath MJ
    J Immunol; 2003 Sep; 171(5):2671-83. PubMed ID: 12928421
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of a biallelic polymorphism in the tumor necrosis factor alpha promoter and HIV type 1 disease progression.
    Knuchel MC; Spira TJ; Neumann AU; Xiao L; Rudolph DL; Phair J; Wolinsky SM; Koup RA; Cohen OJ; Folks TM; Lal RB
    AIDS Res Hum Retroviruses; 1998 Mar; 14(4):305-9. PubMed ID: 9519891
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects.
    Devito C; Hinkula J; Kaul R; Kimani J; Kiama P; Lopalco L; Barass C; Piconi S; Trabattoni D; Bwayo JJ; Plummer F; Clerici M; Broliden K
    J Acquir Immune Defic Syndr; 2002 Aug; 30(4):413-20. PubMed ID: 12138348
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4(+)CD25(+)FOXP3(+) regulatory T cells.
    Card CM; McLaren PJ; Wachihi C; Kimani J; Plummer FA; Fowke KR
    J Infect Dis; 2009 May; 199(9):1318-22. PubMed ID: 19301980
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial.
    Kuebler PJ; Mehrotra ML; McConnell JJ; Holditch SJ; Shaw BI; Tarosso LF; Leadabrand KS; Milush JM; York VA; Raposo RA; Cheng RG; Eriksson EM; McMahan V; Glidden DV; Shiboski S; Grant RM; Nixon DF; Kallás EG
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8379-84. PubMed ID: 26100867
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.
    Heredia A; Gilliam B; Latinovic O; Le N; Bamba D; Devico A; Melikyan GB; Gallo RC; Redfield RR
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2489-96. PubMed ID: 17485501
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cellular immunity and target cell susceptibility in persons with repeated HIV-1 exposure.
    Akridge R; Hladik F; Markee J; Alef C; Kelley H; Collier A; Collier A; McElrath MJ
    Immunol Lett; 1999 Mar; 66(1-3):15-9. PubMed ID: 10203029
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya.
    Fowke KR; Nagelkerke NJ; Kimani J; Simonsen JN; Anzala AO; Bwayo JJ; MacDonald KS; Ngugi EN; Plummer FA
    Lancet; 1996 Nov; 348(9038):1347-51. PubMed ID: 8918278
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of highly active antiretroviral treatment on expression of HIV-1 coreceptors and ligand levels in peripheral blood from HIV-1 infected patients in China.
    Fang J; Bai S; Wu L; Zhu X; Yao X; Jin C; Wang C
    J Int Med Res; 2013 Oct; 41(5):1560-9. PubMed ID: 24043708
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence of a CCR5 gene 32-bp deletion in an Israeli cohort of HIV-1-infected and uninfected hemophilia patients.
    Kantor R; Barzilai A; Varon D; Martinowitz U; Gershoni JM
    J Hum Virol; 1998; 1(4):299-301. PubMed ID: 10195255
    [TBL] [Abstract][Full Text] [Related]  

  • 58. IL-22 participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction.
    Missé D; Yssel H; Trabattoni D; Oblet C; Lo Caputo S; Mazzotta F; Pène J; Gonzalez JP; Clerici M; Veas F
    J Immunol; 2007 Jan; 178(1):407-15. PubMed ID: 17182579
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers.
    Kaul R; Rowland-Jones SL; Kimani J; Fowke K; Dong T; Kiama P; Rutherford J; Njagi E; Mwangi F; Rostron T; Onyango J; Oyugi J; MacDonald KS; Bwayo JJ; Plummer FA
    Immunol Lett; 2001 Nov; 79(1-2):3-13. PubMed ID: 11595284
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele.
    Furci L; Scarlatti G; Burastero S; Tambussi G; Colognesi C; Quillent C; Longhi R; Loverro P; Borgonovo B; Gaffi D; Carrow E; Malnati M; Lusso P; Siccardi AG; Lazzarin A; Beretta A
    J Exp Med; 1997 Aug; 186(3):455-60. PubMed ID: 9236198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.